Please login to the form below

Not currently logged in
Email:
Password:
I have forgotten my password

SMC

This page shows the latest SMC news and features for those working in and with pharma, biotech and healthcare.

SMC enables access to Kyowa Kirin’s Crysvita for adults with rare genetic disease

SMC enables access to Kyowa Kirin’s Crysvita for adults with rare genetic disease

The Scottish Medicines Consortium (SMC) has enabled access to the first treatment addressing the underlying cause of X-linked hypophosphataemia (XLH), a rare and life-long genetic disease that causes abnormalities ... data. Prior to the SMC’s decision,

Latest news

More from news
Approximately 17 fully matching, plus 87 partially matching documents found.

Latest Intelligence

  • NICE – but not enough NICE – but not enough

    Olumiant launched in 2017 and received positive recommendations from NICE and SMC in the middle of Q3 that same year.

  • The Orkambi row explained The Orkambi row explained

    December 2018: Scottish Government agrees a deal with Vertex pending submission of Orkambi and Symkevi to Scottish Medicines Consortium (SMC), with interim access possible through the PACS Tier 2 system.

  • The Orkambi blame game The Orkambi blame game

    Leiden also claimed the breakthrough in Scotland came when NICE’s equivalent, the SMC, agreed to ‘flex’ its methodology – something which he and other industry leaders said is vital if NICE

  • Patient involvement in health technology assessment Patient involvement in health technology assessment

    We have developed a Public Involvement Network (PIN) that formalises relationships with each submitting patient group through a registration process to become an SMC Patient Group Partner. ... SMC as a respected partner in developing and shaping all

  • The reality of real-world evidence The reality of real-world evidence

    Zaltrap re-submission to the Scottish Medicines Consortium (SMC) included RWE (pooled data from two open-label, single-arm studies) to demonstrate prolonged safety and QoL benefit.

More from intelligence
Approximately 0 fully matching, plus 10 partially matching documents found.

Latest from PMHub

  • YorkTown

    decision makers associated with pharmaceutical and medical device/diagnostics market access and HEOR; Developing and writing single technology appraisals (STA) (pharmaceutical and medical device) for regulatory institutions (NICE, EMA, SMC and

  • The Holistic Approach to Market Access

    and to provide local prescribing audit data for inclusion into NICE and SMC technical appraisals the gaining of which is a key element in gaining regional prescribing uptake.

More from PMHub
Approximately 0 fully matching, plus 2 partially matching documents found.

Subscribe to our email news alerts

PMHub

Add my company
Redbow Consulting Group

Redbow Consulting Group is a specialist healthcare management consultancy specialising in business strategy and marketing...

Latest intelligence

The speed of science and the pace of comms
Pharma red tape slows comms but there is a solution, Paul Hutchings, founder of fox&cat, writes....
Improving cardiovascular disease care and awareness
Scott Curley talks to PME about the risks of CVD and the importance of getting the right treatment at the right time...
Virtual Patient Engagement Program: A Customer Story
Our client wanted to better understand the needs, preferences, and treatment gaps among adult patients with a rare genetic disease......

Quick links